In ADPKD patients with PLD, multiple serum bile acids decreased with lanreotide but remained stable in untreated subjects.
In plain wordsIn ADPKD patients with PLD, several serum bile acids decreased with lanreotide but remained stable without treatment.
- Peptide
- Lanreotide
- Outcome
- DecreaseSerum bile acids
- Study
n = 105
- Comparator
- untreated subjects
- Analysis
- Exploratory
- Outcome group
- Liver fat and liver function · Liver
- Studied dose
- Dose not stated · 120 weeksAs given in this study (human).
Source sentences
In PLD patients, multiple bile acids decreased upon treatment with lanreotide but remained stable in untreated subjects.
3 context sentences(design, population, supporting numbers)
We performed a post-hoc exploratory analysis of bile acids in ADPKD patients, who had participated in a trial on the effect of a somatostatin analogue.
With liquid chromatography-mass spectrometry, 11 bile acids in serum and 6 in urine were quantified in 105 PLD ADPKD patients and 52 age-, sex-, mutation- and eGFR-matched non-PLD ADPKD patients.
Sampling was done at baseline and after 120 weeks of either lanreotide or standard care.